Dr. Reddy's Laboratories500124Pharmaceuticals
Dr. Reddy's expected to report a revenue decline of around 4 percent this quarter, led by weakness in its US business
By ScoutQuest · · 1 min read
- Expected revenue decline
- 4 odd percent
- Expected EBITDA decline
- 49 percent
- Expected margin
- 14 to 15 odd percent
- North America revenue decline expected
- 35 percent
- Expected North America revenue
- 235 to 240 million dollars
Heard on business television between 15:15:18 - 15:18:18 IST.
- Ekta said Dr. Reddy's is expected to see a revenue decline of around 4 percent, with EBITDA expected to decline by around 49 percent and margins around 14-15 percent.
- North American business expected to decline by as much as 35 percent due to US competition and lack of key drugs like Remelic generic, with US revenue expected around $235-240 million.
- India business expected to grow 14-15 percent led by pain and gastro segments, aided by deals such as promoting Sanofi's vaccines and a $50 million anti-vertigo drug acquisition from GSK last year.
- Key things to watch include commentary on Semaglutide API and resumption of Semaglutide launch in Canada, plus margin guidance of 20 percent for FY27 and 25 percent longer term.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Dr Reddys Laboratories
Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
24 Oct 2026
Auditor's limited review reports with UDIN on Q2 and H1 results
23 Oct 2026
Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
23 Oct 2026
Source: Live TV News Channel · 23 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.